Seeking Alpha

AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) diabetes drug Onglyza doesn't reduce heart...

AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) diabetes drug Onglyza doesn't reduce heart risks, a large-scale study shows, with patients who suffer from the Type 2 version of the disease not experiencing fewer strokes, heart attacks and other adverse events than those who took a placebo. Investors had hoped that a demonstrable cardiovascular benefit for Onglyza, which generated sales of $709M in 2012, would give it an edge over rival treatments and revive slowing demand. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|